Results 31 to 40 of about 1,470 (198)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. [PDF]

, 2021
The neonatal Fc receptor (FcRn) binds endogenous IgG and protects it from lysosomal degradation by transporting it back to the cell surface to re-enter the circulation, extending the serum IgG life span.
Dalakas, Marinos C., Späth, Peter J.
core   +1 more source

Antibody Therapies in Autoimmune Encephalitis [PDF]

, 2022
Autoimmune encephalitis (AE) comprises a heterogeneous group of disorders in which the host immune system targets self-antigens expressed in the central nervous system.
Smets, I., Titulaer, M. J.
core   +2 more sources

A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients [PDF]

Introduction: Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients.
Bevilacqua, Liliana, Brighina, Filippo, Cuomo, Nunzia, Di Stefano, Vincenzo, Fionda, Laura, Garibaldi, Matteo, Marsili, Angela, Pane, Chiara, Puorro, Giorgia, Rini, Nicasio, Sacca, Francesco, Sarnataro, Alessio, Vinciguerra, Claudia   +12 more
core   +4 more sources

Advances and challenges in the treatment of myasthenia gravis [PDF]

, 2021
Myasthenia gravis (MG) is a chronic autoimmune disease with fluctuating muscle weakness and fatigability. Standard immunomodulatory treatment may fail to achieve sufficient improvement with minimal symptom expression or remission of myasthenic symptoms ...
Gilhus, Nils Erik, Schneider-Gold, Christiane   +1 more
core   +1 more source

Guideline for the management of myasthenic syndromes [PDF]

, 2023
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare chronic diseases.
Abicht, Angela, Chan, Andrew, Della Marina, Adela, Hagenacker, Tim, Hekmat, Khosro, Hoffmann, Hans-Stefan, Hoffmann, Sarah, Jander, Sebastian, Keller, Christian, Marx, Alexander, Meisel, Andreas, Melms, Arthur, Melzer, Nico, Müller-Felber, Wolfgang, Pawlitzki, Marc, Rückert, Jens-Carsten, Schneider-Gold, Christiane, Schoser, Benedikt, Schreiner, Bettina, Schroeter, Michael, Schubert, Bettina, Sieb, Jörn-Peter, Wiendl, Heinz, Zimprich, Fritz   +23 more
core   +1 more source

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) [PDF]

, 2023
There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose disease symptoms are not well controlled.
Barnett, C., Chiroli, S., Gelinas, D., Peric, S., Phillips, G.A., Qi, C.Z., Saccà, F., Verschuuren, J.J.G.M., Vu, T., Zhao, S.H.   +9 more
core   +2 more sources

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial [PDF]

Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances.
Adam Quick, Adriano Chiò, Aihong Guo, Aisling Carr, Alessandro Padovani, Alexander Tsiskaridze, Alexey Boyko, Alla Kyrychenko, Allen, Jeffrey A, Alon Abraham, Amir Dori, Ana-Maria Scutaru-Kadar, Andoni Echaniz-Laguna, Angelo Schenone, Anna Mazzeo, Antonio Guerrero Sola, Any Axelerad, Arnaldo Isa, Basta, Ivana, Benjamin Barnes, Benjamin Hotter, Bhaskar Roy, Bitao Bu, Carmen Diaz Marin, Chang, Ting, Chi-Chao Chao, Chongbo Zhao, Christopher Nance, Collaborators: Susanne Grinzinger, Dale Lange, Dan Mitrea, Daniel Jacob, Daojun Hong, David Lacomis, Dániel Bereczki, De-Hyung Lee, Dian He, Dmytro Smolko, Donna Luke, Dysgaard, Tina, Eduard Yakupov, Eduardo Aguera Morales, Eggers, Christian, Emma Matthews, Eroboghene Ubogu, Etsuji Saji, Fabio Giannini, Farit Khabirov, Fatima Stuchevskaya, Filip Eftimov, Filiz Koç, Fiore Manganelli, Francesca Magri, Francisco Javier Carod-Artal, Frédéric Taithe, Fumiaki Tanaka, Fuqiang Guo, Gabriele Siciliano, Gauthier Remiche, Gregory Sahagian, Guillaume Nicolas, Guntis Karelis, Guptill, Jeffrey T, Gwathmey, Kelly G, Gyula Pánczél, Haishan Jiang, Hamdi Necdet Karli, Han-Wei Huang, Hani Kushlaf, Hewamadduma, Channa, Hiroki Yamazaki, Hofman, Erik, Huan Yang, Hui Liang, Hussain, Yessar M, Ichiro Yabe, Ihsan Sengun, Iryna Skrypchenko, Isaac Melamed, Ivan Milanov, Ivaylo Tarnev, James Scott, Jan Kochanowicz, Jana Zschuentzsch, Jérôme De Seze, Jia-Ying Sung, Jianglong Tu, Jiann-Horng Yeh, Jianquan Shi, Jin Nakahara, Jing Ding, Jonathan Baets, Jonathan Katz, Jose Luis Muñoz Blanco, Julia Wanschitz, Juliane Klehmet, Julien Cassereau, Junhong Guo, Kalliopi Pitarokoili, Karissa Gable, Kathryn Brennan, Kazuhiro Horiuchi, Kazutoshi Nishiyama, Kenichi Kaida, Khema Sharma, Kota Bokuda, Krasimir Genov, Kristl G Claeys, Krzysztof Banaszkiewicz, Krzysztof Selmaj, Kumaraswamy Sivakumar, Kuwabara, Satoshi, Laurent Magy, Lauria, Giuseppe, Le Masson, Gwendal, Lewis, Richard A, Leypoldt, Frank, Lin, Jie, Lipowska, Marta, Long-Sun Ro, Lowe, Murray, Macarena Cabrera Serrano, Maka Mania, Mamatha Pasnoor, Marc Feinberg, Marina Janelidze, Mark Gudesblatt, Mark Stettner, Marta Banach, Masahisa Katsuno, Matthew Elliott, Michael Pulley, Michael Rivner, Michael Schroeter, Motoi Kuwahara, Murat Terzi, Nai-Wen Tsai, Natalia Suponeva, Nataliya Tomakh, Nicolas Dubuisson, Nikolay Dorogov, Norito Kokubun, Olaf Hoffmann, Oleksandr Doroshenko, Oleksandr Kalbus, Olga Seliuk, Olga Shulga, Olha Novakovska, Pantelis Pavlakis, Patrick Kwon, Petra Baum, Plamen Tsvetanov, Priyanka Sabharwal, Querol, Luis, Rabab Debs, Radomir Talab, Raghav Govindarajan, Ranko Raicevic, Ratna Bhavaraju-Sanka, Raúl Juntas Morales, Rebecca Traub, Renxi Xu, Robert Lisak, Roman Shakarishvili, Rup Tandan, Sabrina Sacconi, Sadiq Altamimi, Sami Khella, Samir Macwan, Sandro Sorbi, Satoshi Tomita, Sezin Alpaydin Baslo, Shan Chen, Simon Ellis, Simon Rinaldi, Simu, Mihaela-Adriana, Soeren Sindrup, Stefania Morino, Stephanie Delstanche, Suresh, Niraja, Svetlana Miletic Drakulic, Tahseen Mozaffar, Takamichi Sugimoto, Takanori Yokota, Takashi Tokashiki, Tamar Janelidze, Tatiana Trushnikova, Tatsusada Okuno, Thomas Brannagan, Thomas Harbo, Thomas Seifert-Held, Thomas Skripuletz, Todd Levine, Tomasz Zielinski, Tomohiro Hayashi, Tomoko Okamoto, Tse, Anissa, Ulrichts, Peter, Urszula Chyrchel-Paszkiewicz, van Doorn, Pieter A, Van Hoorick, Benjamin, Véronique Bissay, Wei Li, Xuefan Yu, Yair Lampl, Yali Zhang, Yamasaki, Ryo, Yann Péréon, Yiqi Wang, Yoshihisa Yamano, Yuanqi Zhao, Yuh-Cherng Guo, Yuki Hatanaka, Yunhua Yue, Yuwei Da, Yuzhong Wang, Zabeen Mahuwala, Zhangyu Zou, Zoya Goncharova, Zunbo Li, Zuneng Lu   +220 more
core   +5 more sources

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives [PDF]

, 2022
Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor agonists (TPO-RA), and splenectomy.
Auteri, Giuseppe, Baldacci, Erminia, Bartoletti, Daniela, Buccisano, Francesco, Carrai, Valentina, Clissa, Cristina, Esposito, Daniela, Giuffrida, Gaetano, Magro, Domenico, Palandri, Francesca, Podda, Gian Marco, Rivolti, Elena, Vianelli, Nicola   +12 more
core   +1 more source

Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis [PDF]

Introduction: This study used network meta-analysis (NMA) to inform and compare the number needed to treat (NNT), number needed to harm (NNH), and cost per improved outcome (CPIO) associated with more recently approved treatments for anti-acetylcholine ...
Brauer, Edward, Chen, Xin, Du, Mandy, Gelinas, Deborah, Habib, Ali A, Phillips, Glenn, Qi, Cynthia Z, Sacca, Francesco, Smith, A Gordon, Wolfe, Gil I, Yang, Hongbo   +10 more
core   +1 more source

Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys

Journal of Immunotoxicology
Efgartigimod is a human IgG1 antibody Fc fragment that reduces IgG levels through neonatal Fc receptor blockade. This study evaluated whether efgartigimod affects the generation of T-cell-dependent antibodies and cellular immune responses to keyhole ...
Ornella Binazon, Mario Cocco, Daniel Thwaites, Christopher Cooper, Mahan Moshir, Peter Vanhoenacker, Dieter Defever, Ariëlla Van de Sompel, Sophie Steeland, Gwenda Pynaert, Peter Ulrichts, Judith Baumeister   +11 more
doaj   +1 more source